Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Neutropenia in Myelosuppressed Cancer Patients Treated with Recombinant Human Erythropoietin (EPO)

Daniel G. Wright, MD, Elizabeth C. Wright, PhD MPH, Constance Tom Noguchi, PhD

Blood (2019) 134 (Supplement_1): 1034.

https://doi.org/10.1182/blood-2019-126650

Published: 2019

Journal Articles

B Cell Specific Knockdown of the Erythropoietin (EPO) Receptor Attenuates EPO-Induced Bone Loss in Mice

Albert Kolomansky, MD, Naamit Deshet-Unger, PhD, Nathalie Ben-Califa, PhD, Zamzam Awida, Maria Ibrahim, B.Sc., Tamar Liron, PhD, Sahar Hiram-Bab, PhD, Howard S. Oster, MD PhD, Moshe Mittelman, MD, Martina Rauner, PhD, Ben Wielockx, PhD, Yankel Gabet, DMD, PhD, Drorit Neumann, PhD

Blood (2019) 134 (Supplement_1): 939.

https://doi.org/10.1182/blood-2019-127092

Published: 2019

Journal Articles

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Bruno Fattizzo, MD, Marc Michel, Laetitia Languille, Juri Giannotta, MD, Henrik Frederiksen, MD Prof, Francesca Romana Mauro, MD, Bernd Jilma, Elisa Lucchini, MD, Andrea Patriarca, MD, Francesco Zaja, MD, Anita Hill, MD PhD, Sigbjorn Berentsen, MD PhD, Wilma Barcellini

Blood (2019) 134 (Supplement_1): 3516.

https://doi.org/10.1182/blood-2019-125524

Published: 2019

Journal Articles

Iron Supplementation: What's New?

Iain C. Macdougall, MD

Blood (2017) 130 (Supplement 1): SCI-43.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-43.SCI-43

Published: 2017

Journal Articles

Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial

Norbert Gattermann, MD, Rosa Coll, MD, Lutz Jacobasch, Allameddine Allameddine, Laurie DeBonnett, Amin Azmon, Jie Jin

Blood (2017) 130 (Supplement 1): 2984.

https://doi.org/10.1182/blood.V130.Suppl_1.2984.2984

Published: 2017

Journal Articles

Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodisplastic Syndromes (FISM)

Blood (2016) 128 (22): 4342.

https://doi.org/10.1182/blood.V128.22.4342.4342

Published: 2016

Journal Articles

A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

Suporn Chuncharunee, MD, Nonglak Kanitsap, MD, Tawatchai Suwanban, MD, Archrob Khuhapinant, PhD MD, Noppacharn Uaprasert, MD, Kanchana Chansung, MD, Ekarat Rattarittamrong, MD, Somchai Wongkhantee, MD, Noppadol Siritanaratanakul, MD, Lalita Norasetthada, MD, Thanyaphong Na Nakorn, MD PhD, Chadchai Charnwiboonsri, Bsc.Pharm

Blood (2016) 128 (22): 5543.

https://doi.org/10.1182/blood.V128.22.5543.5543

Published: 2016

Journal Articles

One-Time Administration of Recombinant Human Erythropoietin Decreases B Cell in Human Peripheral Blood

Tomomi Nagashima, Akihiko Yokohama, MD PhD, Kie Nagai, Rumi Ino, Noriyuki Takahashi, Tetsuhiro Kasamatsu, Tomomi Sekigami, Hirono Iriuchishima, MD PhD, Makiko Takizawa, PhDMD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Hirokazu Murakami, MD PhD

Blood (2016) 128 (22): 4899.

https://doi.org/10.1182/blood.V128.22.4899.4899

Published: 2016

Journal Articles

Immune Dysfunction in Patients with MDS Is Partially Corrected in EPO-Treated Patients: Differences According to WHO Classification

Howard S Oster, MD PhD, Naamit Deshet-Unger, MSc, Drorit Neumann, PhD, Moshe Mittelman, MD, Nir Maaravi, MD, Sara Prutchi-Sagiv, PhD, Golishevski Nataliya, MD

Blood (2016) 128 (22): 3165.

https://doi.org/10.1182/blood.V128.22.3165.3165

Published: 2016

Journal Articles

Recombinant Erythropoietin and Darbepoetin Alpha Exert a Similar Dose-Dependent Osteopenic Effect Which May Advocate for "Start Low, Go Slow" Dosing Strategy in Clinical Practice

Kolomansky Albert, MD, Sahar Hiram-Bab, PhD, Naamit Deshet-Unger, MSc, Nathalie Ben-Califa, PhD, Dafna Gilboa, MSc, Tamar Liron, PhD, Howard S Oster, MD PhD, Moshe Mittelman, MD, Yankel Gabet, DMD, PhD, Drorit Neumann, PhD

Blood (2016) 128 (22): 2445.

https://doi.org/10.1182/blood.V128.22.2445.2445

Published: 2016

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

Mathematical Modelling of Erythropoiesis in Patients with End Stage Renal Disease: New Insights into Marrow Functioning

Ashwani K Gupta, MD, Ravneet Bajwa, Olivia Prosper, PhD, Maia Marchetva, PhD

Blood (2015) 126 (23): 3345.

https://doi.org/10.1182/blood.V126.23.3345.3345

Published: 2015

Journal Articles

Erythropoietin May Affect B-Cell Maturation and Plasma Cell Antibody Production in Mice

Howard S Oster, MD PhD, Naamit Deshet-Unger, MS, Max Gassmann, DVM, Moshe Mittelman, MD, Drorit Neumann, PhD

Blood (2015) 126 (23): 4620.

https://doi.org/10.1182/blood.V126.23.4620.4620

Published: 2015

Journal Articles

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Aurélie Jaspers, Frédéric Baron, Évelyne Willems, Laurence Seidel, Kaoutar Hafraoui, Gaetan Vanstraelen, Christophe Bonnet, Yves Beguin

Blood (2014) 124 (1): 33–41.

https://doi.org/10.1182/blood-2014-01-546333

Published: 2014

Includes: Supplemental data

Journal Articles

Interleukin-6 Reduces Erythroid Development and Mitochondrial Membrane Potential In Human Erythroleukemic Cells

Bryan J. McCranor, PhD, MinJung Kim, PhD, Nicole M Cruz, Qian-Li Xue, PhD, Alan E. Berger, PhD, Jeremy D. Walston, M.D., Curt I. Civin, M.D., Cindy N. Roy, PhD

Blood (2013) 122 (21): 3420.

https://doi.org/10.1182/blood.V122.21.3420.3420

Published: 2013

Journal Articles

Erythropoietin Potentiates The Immune System Yet Induces Bone Resorption In a Myeloma Mouse Model

Naamit Deshet-Unger, MSc, Sahar Hiram-Bab, PhD, Mor Gross, Yasmin Haim-Ohana, Miriam C. Souroujon, PhD, Howard S. Oster, MD, PhD, Moshe Mittelman, MD, Yankel Gabet, DMD, PhD, Drorit Neumann, PhD

Blood (2013) 122 (21): 1849.

https://doi.org/10.1182/blood.V122.21.1849.1849

Published: 2013

Journal Articles

Sensitive and Specific Antibody Probes Directed Against The Erythropoietin Receptor – From Basic Studies To Clinical Implementation

Blood (2013) 122 (21): 2175.

https://doi.org/10.1182/blood.V122.21.2175.2175

Published: 2013

Journal Articles

HMGB1 Is a Key Modulator Of Stress Erythropoiesis During Sepsis

Sergio I Valdés-Ferrer, MD, Lionel Blanc, PhD, Sebastien Didier, MSc, Johnson M. Liu, MD, Jeffrey M. Lipton, MD, PhD, Sangeeta S Chavan, PhD, Kevin J Tracey, MD

Blood (2013) 122 (21): 8.

https://doi.org/10.1182/blood.V122.21.8.8

Published: 2013

Journal Articles

ACE-536 Improves Ineffective Erythropoiesis, Anemia and Co-Morbidities in β-Thalassemia

Rajasekhar NVS Suragani, Robert Li, Sharon Cawley, Stefano Rivella, PhD, R. Scott Pearsall, Ravindra Kumar

Blood (2012) 120 (21): 248.

https://doi.org/10.1182/blood.V120.21.248.248

Published: 2012

Journal Articles

Therapeutic Superiority and Safety of Combined Hydroxyurea with Recombinant Human Erythropoietin Over Hydroxyurea in B-Thalassemia Intermedia Patients

Mohsen Saleh Elalfy, Amira Adly, Yassmine Elhanawy

Blood (2012) 120 (21): 252.

https://doi.org/10.1182/blood.V120.21.252.252

Published: 2012

NARROW

Neutropenia in Myelosuppressed Cancer Patients Treated with Recombinant Human Erythropoietin (EPO)

B Cell Specific Knockdown of the Erythropoietin (EPO) Receptor Attenuates EPO-Induced Bone Loss in Mice

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Iron Supplementation: What's New?

Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial

Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodisplastic Syndromes (FISM)

A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

One-Time Administration of Recombinant Human Erythropoietin Decreases B Cell in Human Peripheral Blood

Immune Dysfunction in Patients with MDS Is Partially Corrected in EPO-Treated Patients: Differences According to WHO Classification

Recombinant Erythropoietin and Darbepoetin Alpha Exert a Similar Dose-Dependent Osteopenic Effect Which May Advocate for "Start Low, Go Slow" Dosing Strategy in Clinical Practice

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Mathematical Modelling of Erythropoiesis in Patients with End Stage Renal Disease: New Insights into Marrow Functioning

Erythropoietin May Affect B-Cell Maturation and Plasma Cell Antibody Production in Mice

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Interleukin-6 Reduces Erythroid Development and Mitochondrial Membrane Potential In Human Erythroleukemic Cells

Erythropoietin Potentiates The Immune System Yet Induces Bone Resorption In a Myeloma Mouse Model

Sensitive and Specific Antibody Probes Directed Against The Erythropoietin Receptor – From Basic Studies To Clinical Implementation

HMGB1 Is a Key Modulator Of Stress Erythropoiesis During Sepsis

ACE-536 Improves Ineffective Erythropoiesis, Anemia and Co-Morbidities in β-Thalassemia

Therapeutic Superiority and Safety of Combined Hydroxyurea with Recombinant Human Erythropoietin Over Hydroxyurea in B-Thalassemia Intermedia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only